Want to see LNTH full AI Analyst Report?
Top Page
Lantheus
(NASDAQ:LNTH)
Select Model
Select Model
Rating:69Neutral
Price Target:
$109.00
▲(8.06% Upside)
Action:Downgraded
Date:10/02/26
The score is primarily supported by strong cash flow generation and solid operating profitability with improved leverage. Offsetting this are weak near-term technical signals (negative MACD, RSI < 40, price below key short-term averages) and only moderate valuation appeal at ~23.7x earnings. Corporate events add both potential upside (cash + CVR) and meaningful deal/regulatory and litigation risk, keeping the overall score in the upper-middle range.
Positive Factors
Strong cash generation
Robust operating and free cash flow give Lantheus meaningful internal funding capacity for product development, manufacturing and commercialization. Strong cash conversion also improves resilience and financial flexibility, supporting continued investment without relying solely on external capital over the next several quarters.
Negative Factors
Bottom-line earnings volatility
Declining net income despite healthy gross and operating margins shows that below-the-line results have been inconsistent. Such volatility can reduce the reliability of reported earnings, complicate planning and weaken the company’s ability to translate operating strength into steadily growing shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Robust operating and free cash flow give Lantheus meaningful internal funding capacity for product development, manufacturing and commercialization. Strong cash conversion also improves resilience and financial flexibility, supporting continued investment without relying solely on external capital over the next several quarters.
Read all positive factors
Lantheus (LNTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.53B
Dividend YieldN/A
Average Volume (3M)1.01M
Price to Earnings (P/E)23.7
Beta (1Y)0.37
Revenue Growth2.35%
EPS Growth7.38%
CountryUS
Employees1,193
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.21
Shares Outstanding65,299,870
10 Day Avg. Volume1,089,831
30 Day Avg. Volume1,005,103
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue4.83
Enterprise Value/Gross Profit8.04
Enterprise Value/Ebitda16.16
Forecast
1Y Price Target
$105.48Price Target Upside4.57% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)5.41
Revenue Forecast (FY)$1.48B
Lantheus Business Overview & Revenue Model
Company Description
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis...
How the Company Makes Money
Lantheus makes money primarily by selling diagnostic imaging agents (radiopharmaceuticals and related products) to hospitals, imaging centers, and radiopharmacies for use in patient imaging procedures. Revenue is generated when customers purchase ...
Lantheus Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Neutral
The call contained meaningful positives — regulatory progress with PYLARIFY TRUVU approval, solid cash generation, NEUROCEQ and DEFINITY growth, and a reaffirmed full-year outlook — balanced against near-term profitability pressure driven by lower oncology reported revenue, higher operating expenses from recent acquisitions and investments, competitive and pricing risks in PSMA PET, and regulatory timing uncertainty for some therapeutic assets. Management emphasized disciplined capital allocation and readiness to launch TRUVU, and expects growth acceleration in 2027, but near-term headwinds keep the tone measured.Positive Updates
FDA Approval of PYLARIFY TRUVU
FDA approved PYLARIFY TRUVU on March 6, 2026. The new formulation offers larger batch sizes and improved stability at higher radioactive concentrations, enabling broader geographic reach and supply flexibility. Management estimates >70% of current PYLARIFY supply is produced at PMF sites equipped to realize TRUVU advantages.
Negative Updates
Oncology Revenue Decline (PYLARIFY reported revenue)
Oncology revenue (PYLARIFY) was $240.9 million in Q1, down 6.5% year-over-year despite volume growth, reflecting net price pressure and competitive dynamics in the PSMA PET space.
Read all updates
Q1-2026 Updates
Positive
Negative
FDA Approval of PYLARIFY TRUVU
FDA approved PYLARIFY TRUVU on March 6, 2026. The new formulation offers larger batch sizes and improved stability at higher radioactive concentrations, enabling broader geographic reach and supply flexibility. Management estimates >70% of current PYLARIFY supply is produced at PMF sites equipped to realize TRUVU advantages.
Read all positive updates
Company Guidance
Lantheus reiterated full‑year 2026 guidance of $1.40–$1.45 billion in revenue and $5.00–$5.25 in adjusted EPS while citing a strong Q1 start: Q1 revenue $377.3M (+1.2% YoY; +8.6% ex‑$25.2M divested spec revenue), reported net income $118.4M and adjusted net income $95.8M (‑12.5% YoY), GAAP diluted EPS $1.80 and adjusted EPS $1.46 (down ~4.6%), operating profit $129.1M (‑10.5%), gross margin 67.0%, operating expenses 32.8% of revenue, and an effective tax rate of 25.3%; product level Q1 results included PYLARIFY $240.9M (‑6.5% YoY; U.S. volume +5.8% YoY), NEUROCEQ $35.4M (+14.3% vs Q4 2025), DEFINITY $84.6M (+6.8% YoY) and strategic partnerships $16.3M (+52.1%). Cash generation remained strong with operating cash flow $125.1M, capex $3.2M, free cash flow $121.9M, cash & equivalents $498.6M, $200M remaining on the buyback authorization and a $750M undrawn revolver; management said guidance is being maintained out of prudence given competitive dynamics and an upcoming CEO transition, while expecting growth acceleration beginning in 2027.Lantheus Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56B | 1.54B | 1.53B | 1.30B | 935.06M | 425.21M |
| Gross Profit | 936.02M | 941.95M | 988.29M | 709.54M | 581.70M | 187.69M |
| EBITDA | 465.39M | 403.64M | 515.27M | 491.00M | 81.83M | -25.00M |
| Net Income | 275.31M | 233.56M | 312.44M | 326.66M | 28.07M | -71.28M |
Balance Sheet | ||||||
| Total Assets | 2.41B | 2.23B | 1.98B | 1.65B | 1.32B | 863.78M |
| Cash, Cash Equivalents and Short-Term Investments | 593.30M | 359.12M | 912.81M | 713.66M | 415.65M | 98.51M |
| Total Debt | 624.96M | 619.43M | 619.44M | 616.95M | 583.51M | 191.31M |
| Total Liabilities | 1.10B | 1.14B | 892.33M | 835.26M | 874.11M | 399.35M |
| Stockholders Equity | 1.31B | 1.09B | 1.09B | 815.89M | 447.15M | 464.44M |
Cash Flow | ||||||
| Free Cash Flow | 387.83M | 354.05M | 493.13M | 258.70M | 263.43M | 41.78M |
| Operating Cash Flow | 412.80M | 390.14M | 544.75M | 305.26M | 281.78M | 53.92M |
| Investing Cash Flow | -307.01M | -627.17M | -226.01M | 5.94M | -276.55M | 3.68M |
| Financing Cash Flow | -207.07M | -316.58M | -118.54M | -13.06M | 311.69M | -39.33M |
Lantheus Technical Analysis
Neutral
100.87
Price Trends
100.78
Negative
101.69
Negative
88.07
Positive
Market Momentum
-0.37
Negative
44.81
Neutral
31.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Neutral. The current price of 100.87 is above the 20-day moving average (MA) of 100.19, above the 50-day MA of 100.78, and above the 200-day MA of 88.07, indicating a neutral trend. The MACD of -0.37 indicates Negative momentum. The RSI at 44.81 is Neutral, neither overbought nor oversold. The STOCH value of 31.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LNTH.
Lantheus Risk Analysis
Lantheus disclosed 67 risk factors in its most recent earnings report. Lantheus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lantheus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.58B | 119.05 | 40.13% | ― | 81.49% | ― | |
69 Neutral | $6.53B | 23.74 | 23.27% | ― | 2.35% | 7.38% | |
69 Neutral | $1.00B | 71.60 | 2.13% | ― | 5.71% | ― | |
68 Neutral | $1.66B | 14.94 | 19.19% | ― | 30.90% | ― | |
68 Neutral | $1.08B | 14.61 | 10.11% | 3.43% | 1.02% | -38.09% | |
66 Neutral | $2.50B | 155.01 | 1.43% | ― | -8.81% | -96.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
LNTH
Lantheus
99.96
47.26
89.68%
PCRX
Pacira Pharmaceuticals
25.21
1.34
5.61%
ANIP
ANI Pharmaceuticals
72.18
-19.88
-21.59%
AMPH
Amphastar Pharmaceuticals
25.43
-1.15
-4.33%
HCM
HUTCHMED
14.20
-2.01
-12.40%
ETON
Eton Pharmaceuticals
55.36
34.63
167.05%
Lantheus Corporate Events
Legal ProceedingsM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Lantheus Issues Supplemental Disclosures Ahead Curium Merger Vote
Negative
Oct 2, 2026
On August 3, 2026, Lantheus agreed to be acquired via a merger with Curium US Holdings LLC, under which Lantheus will become a wholly owned subsidiary following a shareholder vote at a special meeting scheduled for October 14, 2026. The company fi...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Lantheus Merger Advances with Renewed Antitrust Review
Positive
Sep 21, 2026
On August 3, 2026, Lantheus Holdings, Inc. agreed to be acquired through a merger with Curium US Holdings LLC, under which Lantheus will become a wholly owned subsidiary of Curium. As part of the regulatory process, Curium, in consultation with La...
Business Operations and StrategyDelistings and Listing ChangesM&A Transactions
Curium to Acquire Lantheus, Taking Company Private
Positive
Aug 4, 2026
On August 3, 2026, Lantheus agreed to be acquired by Curium US Holdings via a merger that will take Lantheus private as a wholly owned subsidiary, with shareholders receiving $102.50 in cash per share plus a non-tradeable contingent value right of...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Curium to Acquire Lantheus in $8 Billion Merger
Positive
Aug 3, 2026
On August 3, 2026, Curium US Holdings and Lantheus agreed to a merger in which Curium will acquire all Lantheus shares for $102.50 in cash at closing, plus up to $12.00 per share in non-transferable contingent value rights tied to 2030 sales miles...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.